Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TENM2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TENM2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TENM2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TENM2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
GO:006049118 | Esophagus | ESCC | regulation of cell projection assembly | 110/8552 | 188/18723 | 2.60e-04 | 1.58e-03 | 110 |
GO:012003218 | Esophagus | ESCC | regulation of plasma membrane bounded cell projection assembly | 108/8552 | 186/18723 | 4.37e-04 | 2.46e-03 | 108 |
GO:01200347 | Esophagus | ESCC | positive regulation of plasma membrane bounded cell projection assembly | 64/8552 | 105/18723 | 1.15e-03 | 5.70e-03 | 64 |
GO:003134610 | Oral cavity | OSCC | positive regulation of cell projection organization | 176/7305 | 353/18723 | 1.94e-05 | 1.87e-04 | 176 |
GO:006049110 | Oral cavity | OSCC | regulation of cell projection assembly | 100/7305 | 188/18723 | 5.27e-05 | 4.38e-04 | 100 |
GO:012003216 | Oral cavity | OSCC | regulation of plasma membrane bounded cell projection assembly | 98/7305 | 186/18723 | 1.00e-04 | 7.54e-04 | 98 |
GO:01200346 | Oral cavity | OSCC | positive regulation of plasma membrane bounded cell projection assembly | 55/7305 | 105/18723 | 3.64e-03 | 1.51e-02 | 55 |
GO:006049116 | Oral cavity | LP | regulation of cell projection assembly | 66/4623 | 188/18723 | 8.62e-04 | 7.49e-03 | 66 |
GO:012003217 | Oral cavity | LP | regulation of plasma membrane bounded cell projection assembly | 64/4623 | 186/18723 | 1.81e-03 | 1.37e-02 | 64 |
GO:003134615 | Oral cavity | LP | positive regulation of cell projection organization | 109/4623 | 353/18723 | 4.59e-03 | 2.93e-02 | 109 |
GO:003134617 | Skin | AK | positive regulation of cell projection organization | 60/1910 | 353/18723 | 5.24e-05 | 8.10e-04 | 60 |
GO:012003219 | Skin | AK | regulation of plasma membrane bounded cell projection assembly | 33/1910 | 186/18723 | 1.13e-03 | 8.75e-03 | 33 |
GO:006049119 | Skin | AK | regulation of cell projection assembly | 33/1910 | 188/18723 | 1.36e-03 | 1.01e-02 | 33 |
GO:01200348 | Skin | AK | positive regulation of plasma membrane bounded cell projection assembly | 19/1910 | 105/18723 | 9.43e-03 | 4.60e-02 | 19 |
GO:00987421 | Skin | SCCIS | cell-cell adhesion via plasma-membrane adhesion molecules | 26/919 | 273/18723 | 9.83e-04 | 1.23e-02 | 26 |
GO:003134618 | Skin | SCCIS | positive regulation of cell projection organization | 30/919 | 353/18723 | 2.54e-03 | 2.44e-02 | 30 |
GO:003134622 | Skin | cSCC | positive regulation of cell projection organization | 120/4864 | 353/18723 | 4.49e-04 | 3.44e-03 | 120 |
GO:0060491110 | Skin | cSCC | regulation of cell projection assembly | 65/4864 | 188/18723 | 5.34e-03 | 2.69e-02 | 65 |
GO:0120032110 | Skin | cSCC | regulation of plasma membrane bounded cell projection assembly | 64/4864 | 186/18723 | 6.40e-03 | 3.13e-02 | 64 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TENM2 | SNV | Missense_Mutation | novel | c.5662G>A | p.Glu1888Lys | p.E1888K | | protein_coding | tolerated(0.06) | probably_damaging(0.979) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
TENM2 | SNV | Missense_Mutation | novel | c.7237N>C | p.Ser2413Pro | p.S2413P | | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
TENM2 | SNV | Missense_Mutation | novel | c.648N>G | p.Ser216Arg | p.S216R | | protein_coding | tolerated(0.38) | benign(0.189) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
TENM2 | SNV | Missense_Mutation | | c.1229N>G | p.Asp410Gly | p.D410G | | protein_coding | deleterious(0.01) | possibly_damaging(0.517) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TENM2 | SNV | Missense_Mutation | novel | c.988N>T | p.Met330Leu | p.M330L | | protein_coding | tolerated(0.19) | benign(0) | TCGA-AC-A23G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
TENM2 | SNV | Missense_Mutation | | c.2093N>A | p.Ser698Tyr | p.S698Y | | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TENM2 | SNV | Missense_Mutation | | c.4819N>A | p.Leu1607Ile | p.L1607I | | protein_coding | tolerated(0.2) | probably_damaging(0.979) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TENM2 | SNV | Missense_Mutation | rs751325623 | c.3127C>T | p.Arg1043Cys | p.R1043C | | protein_coding | deleterious(0) | possibly_damaging(0.901) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TENM2 | SNV | Missense_Mutation | | c.897N>C | p.Gln299His | p.Q299H | | protein_coding | tolerated(0.13) | possibly_damaging(0.742) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TENM2 | SNV | Missense_Mutation | rs745482697 | c.4841G>A | p.Arg1614Gln | p.R1614Q | | protein_coding | tolerated(0.22) | probably_damaging(0.975) | TCGA-BH-A0H9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |